Dandekar Atul Sells 7,500 Maze Therapeutics (MAZE) Shares at $27.06 Each – Transaction Totals $202,920

Dandekar Atul, Chief Strategy & Business Officer (CSBO) of Maze Therapeutics, Inc., sold on October 2, 2026, 7,500 shares of the company at $27.06 per share, for a total value of $202,920.

Who is Dandekar Atul and What is His Real Role at Maze Therapeutics, Inc.

Dandekar Atul holds the position of Chief Strategy & Business Officer, a leadership role that combines long-term strategy definition and oversight of business operations. As an executive committee member, he participates in meetings where research directions, licensing agreements, and funding decisions are discussed, giving him access to non-public information about the company's clinical projects and market outlook. His role also involves communication with institutional investors, placing him at the heart of information flows that could influence the stock price.

The CSBO is not just an operational manager; he acts as a bridge between the scientific leadership and commercial partners, and is regularly informed about clinical trial results, partnership decisions, and regulatory changes. These elements are considered insider information under securities regulations, which is why any transaction in company shares must be reported within two business days of the transaction via the SEC Form 4.

Transaction Details: 7,500 Shares at $27.06 Each

The SEC Form 4 filed on October 2, 2026, indicates that Dandekar Atul transferred ownership of 7,500 ordinary shares of Maze Therapeutics, Inc. (ticker MAZE). The price per share, as reported, was $27.06, bringing the gross transaction value to $202,920. No other type of financial instrument (options, derivatives) is mentioned in the document, with the transaction limited to a cash sale of shares.

As required by the Securities and Exchange Commission (SEC), the filing was made public via the EDGAR system, ensuring transparency for shareholders and the market. The official link to the filing is https://www.sec.gov/Archives/edgar/data/2050167/000205016726000030/0002050167-26-000030-index.htm, where investors can view the complete form.

Why Insiders Sell Their Shares – Possible Reasons

A share sale by an executive may result from several motivations that are not necessarily linked to the company's future performance. Portfolio diversification is a common reason; an executive may decide to reduce their exposure to a single company to limit overall risk. Tax planning is also a factor, particularly when a sale coincides with a fiscal year-end or the realization of taxable gains.

Personal liquidity needs, such as funding real estate projects or settling family obligations, may prompt the liquidation of part of the shares held. In some cases, the sale is part of a prearranged selling plan (10b-plan), where executives execute periodic transactions to avoid market manipulation accusations. It's also important to note that while the transaction is labeled a "bearish signal" by observers, the insider may sell for purely personal reasons without anticipating a stock price reversal.

How Individual Investors Track Form 4 Filings

Form 4 filings are freely accessible on the SEC website via the EDGAR system. Specialized platforms aggregate this data and offer filters by company, transaction type (buy or sell), and insider role. Tools like OpenInsider, WhaleWisdom, or Bloomberg's "Insider Transactions" module provide real-time alerts when a filing is made.

It's important to keep in mind the limitations of Form 4 information. The filing does not specify the exact motivations of the seller or the market conditions at the time of the transaction. Additionally, the transaction size should be put into perspective with the insider's total portfolio and the stock's average daily volume. Individual investors are therefore encouraged to combine Form 4 analysis with other fundamental and technical indicators before making a buy or sell decision.